Database : MEDLINE
Search on : Sclerosis [Words]
References found : 197800 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 19780 go to page                         

  1 / 197800 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 27057932
[Au] Autor:Vandecasteele E; De Pauw M; De Keyser F; Decuman S; Deschepper E; Piette Y; Brusselle G; Smith V
[Ad] Address:Department of Cardiology, Ghent University Hospital, Ghent, Belgium. Electronic address: els.vandecasteele@ugent.be....
[Ti] Title:Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis.
[So] Source:Int J Cardiol;212:265-73, 2016 Jun 1.
[Is] ISSN:1874-1754
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:BACKGROUND: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of death in systemic sclerosis (SSc). Although the six-minute walk test (6MWT) is generally used for evaluating PAH and ILD, utility in SSc is undetermined. This study evaluates the role of 6MWT in SSc by systematic review and meta-analysis. METHODS: A systematic literature search on PubMed, Web of Science and Cochrane Library Online was performed using the medical subject heading search terms for "systemic sclerosis", "CREST" and "six minute walk test", "six minute walk distance (6MWD)", "(cardiopulmonary) exercise test", "treadmill test" or "step test". RESULTS: Meta-analysis of 43 included studies (3185 SSc-all patients) revealed that the mean 6MWD was comparable between the SSc-PAH and SSc-ILD-PH subgroups (288m [95% CI: 259-317m] vs 286m [95% CI: 259-314m], p=0.93). The pooled mean of 725 SSc-PAH patients was significantly lower than the pooled mean of 413 SSc-noPAH patients (430m [95% CI: 402-458m], p<0.001). 95 SSc-ILD-PH patients walked significantly less than 328 SSc-ILD patients (388m [95% CI: 362-415m], p<0.001) and significantly less than 86 SSc-noILD patients (420m [95% CI: 325-515m], p=0.008). 81-98% of the SSc-PAH/ILD/ILD-PH patients performed a 6MWT. CONCLUSIONS: During a 6MWT, SSc-PAH patients walk less than SSc-noPAH patients and SSc-ILD-PH patients walk less than SSc-ILD and SSc-noILD patients.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1604
[Js] Journal subset:IM
[St] Status:In-Data-Review

  2 / 197800 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26988104
[Au] Autor:Shehab AA; El-Batea HE; El-Din IS; Elfert AA
[Ad] Address:Department of Anatomy, Tanta University, Tanta, Egypt....
[Ti] Title:N-butyl cyanoacrylate- and alpha-cyanoacrylate induced hepatotoxicity and venous sclerosis in a rabbit model.
[So] Source:Arab J Gastroenterol;17(1):3-10, 2016 Mar.
[Is] ISSN:2090-2387
[Cp] Country of publication:Egypt
[La] Language:eng
[Ab] Abstract:BACKGROUND AND STUDY AIMS: Tissue adhesives are commonly used. The aim of this study was to assess the efficacy and hepatotoxicity of intravenous injection of N-butyl cyanoacrylate versus alpha-cyanoacrylate in a rabbit model. MATERIALS AND METHODS: A total of 20 rabbits were divided into three groups: group I included four rabbits injected with lipiodol in the dorsal vein of a pinna (control group); group II included eight rabbits injected with N-butyl cyanoacrylate/lipiodol; and group III included eight rabbits injected with alpha-cyanoacrylate/lipiodol. All animals were left under normal living conditions for 1week, and then euthanised. Specimens of ear and liver were taken and fixed in 10% formalin saline for histological examination. Secondary fixation was performed using Bouin solution. Specimens of ear were decalcified in ethylenediaminetetraacetic acid (EDTA) at room temperature for 3months. Then, all specimens were processed, embedded in paraffin, sectioned, and stained with haematoxylin and eosin stains for microscopic examination. RESULTS: Microscopic examination of all specimens of the control group revealed normal structure of pinna and liver tissue. Both test groups demonstrated a wide variability of structural changes ranging from oedema and congestion to necrosis and marked cellular inflammatory infiltration. The two groups were compared using a self-designed inflammatory score. This revealed that alpha-cyanoacrylate caused more venous sclerosis with extensive perivenous reaction and hepatotoxicity than both N-butyl cyanoacrylate and control (p<0.05 and p<0.05). N-butyl cyanoacrylate was also found to cause more venous sclerosis and hepatotoxicity than control (p<0.05). CONCLUSION: This study suggested that injection of Krazy Glue, either the clinically usable N-butyl cyanoacrylate or the commercially available alpha-cyanoacrylate, caused comparable venous sclerosis. Unfortunately, both induced significant hepatotoxicity. Therefore, neither of them should be used unless all other safe options are absent. Larger studies have to be conducted and effects of these components on other organs should be investigated; however, caution must be exercised in their clinical use.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1604
[Js] Journal subset:IM
[St] Status:In-Data-Review

  3 / 197800 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26807760
[Au] Autor:Jimenez SA; Piera-Velazquez S
[Ad] Address:Jefferson Institute of Molecular Medicine, Thomas Jefferson University, 233 S. 10th Street, Suite 509 BLSB, Philadelphia, PA 19107, USA; Scleroderma Center, Thomas Jefferson University, 233 S. 10th Street, Suite 509 BLSB, Philadelphia, PA 19107, USA; Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, 233 S. 10th Street, Suite 509 BLSB, Philadelphia, PA 19107, USA; Sidney Kimmel Medical College, Thomas Jefferson University, 233 S. 10th Street, Suite 509 BLSB, Philadelphia, PA 19107, USA. Electronic address: sergio.jimenez@jefferson.edu.
[Ti] Title:Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
[So] Source:Matrix Biol;51:26-36, 2016 Apr.
[Is] ISSN:1569-1802
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by progressive fibrosis of skin and multiple internal organs and severe functional and structural microvascular alterations. SSc is considered to be the prototypic systemic fibrotic disorder. Despite currently available therapeutic approaches SSc has a high mortality rate owing to the development of SSc-associated interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), complications that have emerged as the most frequent causes of disability and mortality in SSc. The pathogenesis of the fibrotic process in SSc is complex and despite extensive investigation the exact mechanisms have remained elusive. Myofibroblasts are the cells ultimately responsible for tissue fibrosis and fibroproliferative vasculopathy in SSc. Tissue myofibroblasts in SSc originate from several sources including expansion of quiescent tissue fibroblasts and tissue accumulation of CD34+ fibrocytes. Besides these sources, myofibroblasts in SSc may result from the phenotypic conversion of endothelial cells into activated myofibroblasts, a process known as endothelial to mesenchymal transition (EndoMT). Recently, it has been postulated that EndoMT may play a role in the development of SSc-associated ILD and PAH. However, although several studies have described the occurrence of EndoMT in experimentally induced cardiac, renal, and pulmonary fibrosis and in several human disorders, the contribution of EndoMT to SSc-associated ILD and PAH has not been generally accepted. Here, the experimental evidence supporting the concept that EndoMT plays a role in the pathogenesis of SSc-associated ILD and PAH will be reviewed.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1604
[Cu] Class update date: 160423
[Lr] Last revision date:160423
[Js] Journal subset:IM
[St] Status:In-Data-Review

  4 / 197800 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 27098452
[Au] Autor:Hatton AL; Dixon J; Rome K; Brauer SG; Williams K; Kerr G
[Ad] Address:School of Health and Rehabilitation Sciences, Therapies Building (84A), The University of Queensland, Brisbane, QLD, 4072, Australia. a.hatton1@uq.edu.au....
[Ti] Title:The effects of prolonged wear of textured shoe insoles on gait, foot sensation and proprioception in people with multiple sclerosis: study protocol for a randomised controlled trial.
[So] Source:Trials;17(1):208, 2016.
[Is] ISSN:1745-6215
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Many people with multiple sclerosis experience problems with walking, which can make daily activities difficult and often leads to falls. Foot sensation plays an important role in keeping the body balanced whilst walking; however, people with multiple sclerosis often have poor sensation on the soles of their feet. Wearing a specially designed shoe insole, which enhances plantar sensory information, could help people with multiple sclerosis to walk better. This study will explore whether long-term wear of a textured insole can improve walking in people with multiple sclerosis. METHODS: A prospective randomised controlled trial with two parallel groups will be conducted aiming to recruit 176 people with multiple sclerosis living in the community (Brisbane, Australia). Adults with a clinical diagnosis of multiple sclerosis, Disease Steps score 1-4, who are ambulant over 100 m and who meet specific inclusion criteria will be recruited. Participants will be randomised to a smooth control insole (n = 88) or textured insole (n = 88) group. The allocated insole will be worn for 12-weeks within participants' own footwear, with self-report wear diaries and falls calendars being completed over this period. Blinded assessors will conduct two baseline assessments and one post-intervention assessment. Gait tasks will be completed barefoot, wearing standardised footwear only, and wearing standardised footwear with smooth and textured insoles. The primary outcome measure will be mediolateral base of support when walking over even and uneven surfaces. Secondary measures include spatiotemporal gait parameters (stride length, stride time variability, double-limb support time, velocity), gait kinematics (hip, knee, and ankle joint angles, toe clearance, trunk inclination, arm swing, mediolateral pelvis/head displacement), foot sensation (light touch-pressure, vibration, two-point discrimination) and proprioception (ankle joint position sense). Group allocation will be concealed and all analyses will be based on an intention-to-treat principle. DISCUSSION: This study will explore the effects of wearing textured insoles over 12-weeks on gait, foot sensation and proprioception in people with multiple sclerosis. The study has the potential to identify a new, evidence-based footwear intervention which has the capacity to enhance mobility and independent living in people with multiple sclerosis. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12615000421538 . Registered 4 May 2015.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1604
[Cu] Class update date: 160423
[Lr] Last revision date:160423
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1186/s13063-016-1337-x

  5 / 197800 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 27099767
[Au] Autor:Strickland FM; Patel D; Khanna D; Somers E; Robida AM; Pihalja M; Swartz R; Marder W; Richardson B
[Ad] Address:Rheumatology Division, Department of Internal Medicine , The University of Michigan Medical School , Ann Arbor, Michigan , USA....
[Ti] Title:Characterisation of an epigenetically altered CD4(+) CD28(+) Kir(+) T cell subset in autoimmune rheumatic diseases by multiparameter flow cytometry.
[So] Source:Lupus Sci Med;3(1):e000147, 2016.
[Is] ISSN:2053-8790
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVES: Antigen-specific CD4(+) T cells epigenetically modified with DNA methylation inhibitors overexpress genes normally suppressed by this mechanism, including CD11a, CD70, CD40L and the KIR gene family. The altered cells become autoreactive, losing restriction for nominal antigen and responding to self-class II major histocompatibility complex (MHC) molecules without added antigen, and are sufficient to cause a lupus-like disease in syngeneic mice. T cells overexpressing the same genes are found in patients with active lupus. Whether these genes are co-overexpressed on the same or different cells is unknown. The goal of this study was to determine whether these genes are overexpressed on the same or different T cells and whether this subset of CD4(+) T cells is also present in patients with lupus and other rheumatic diseases. METHODS: Multicolour flow cytometry was used to compare CD11a, CD70, CD40L and KIR expression on CD3(+)CD4(+)CD28(+) T cells to their expression on experimentally demethylated CD3(+)CD4(+)CD28(+) T cells and CD3(+)CD4(+)CD28(+) T cells from patients with active lupus and other autoimmune diseases. RESULTS: Experimentally demethylated CD4(+) T cells and T cells from patients with active lupus have a CD3(+)CD4(+)CD28(+)CD11a(hi)CD70(+)CD40L(hi)KIR(+) subset, and the subset size is proportional to lupus flare severity. A similar subset is found in patients with other rheumatic diseases including rheumatoid arthritis, systemic sclerosis and Sjögren's syndrome but not retroperitoneal fibrosis. CONCLUSIONS: Patients with active autoimmune rheumatic diseases have a previously undescribed CD3(+)CD4(+)CD28(+)CD11a(hi)CD70(+)CD40L(hi)KIR(+) T cell subset. This subset may play an important role in flares of lupus and related autoimmune rheumatic diseases, provide a biomarker for disease activity and serve as a novel therapeutic target for the treatment of lupus flares.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1604
[Cu] Class update date: 160423
[Lr] Last revision date:160423
[Da] Date of entry for processing:160421
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.1136/lupus-2016-000147

  6 / 197800 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text

[PMID]: 27099806
[Au] Autor:Jaruvongvanich V; Spanuchart I; O-Charoen P; Kitamura C; Sumida L; Roytman M
[Ad] Address:Department of Internal Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI (VJ, IS, PO, CK, MR)....
[Ti] Title:An Unusual Cause of Altered Mental Status in Multiple Myeloma: An Extraosseous Manifestation.
[So] Source:Hawaii J Med Public Health;75(4):109-12, 2016 Apr.
[Is] ISSN:2165-8242
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Multiple myeloma typically presents as lytic bony lesions, hypercalcemia, anemia, and renal failure. Extraosseous manifestations are rare. We report on a patient who was recently diagnosed with multiple myeloma and completed the first cycle of bortezomib, dexamethasone, and palliative radiation therapy with good response. Two weeks after discharge, she became confused and was re-admitted. Despite treatment with lactulose and rifaximin, altered mental status worsened. Computer tomographic scan of abdomen showed hepatomegaly and numerous ill-defined small hyperdense nodules scattered throughout the liver. Liver biopsy demonstrated aggregation of plasma cell myeloma. Magnetic resonance imaging of brain revealed dural thickening. Patient's altered mental status was likely from leptomeningeal myelomatosis and hyperammonemic encephalopathy. Although extraosseous manifestations in multiple myeloma including liver and leptomeningeal involvement are rare, its incidence has increased. This condition portends a poor prognosis. The non-specific manifestations of extraosseous myeloma can be confused with complications of multiple sclerosis and lead to incorrect management, thus clinicians should be aware of these pathologies and perform proper diagnostic tests including imaging and tissue pathology. The most effective treatment is unknown, however bortezomib and thalidomide show promise.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1604
[Cu] Class update date: 160423
[Lr] Last revision date:160423
[Js] Journal subset:IM
[St] Status:In-Data-Review

  7 / 197800 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 27099848
[Au] Autor:Vesal S; Dehghani L; Etemadifar M; Poorazizi E; Akhavan S; Mazrouei S; Mehdizadeh N; Saraf Z
[Ad] Address:Isfahan Neurosciences Research Center, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran....
[Ti] Title:Effect of disease duration on personality type in multiple sclerosis patients and healthy individual.
[So] Source:Adv Biomed Res;5:35, 2016.
[Is] ISSN:2277-9175
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:BACKGROUND: Multiple sclerosis may have profound emotional consequences. The relation between psychological and physical factors could lead patients toward unforeseen disease. This study focuses on multiple sclerosis (MS) disease duration on personality type A and B in relation to individuals' behaviors. MATERIALS AND METHODS: This descriptive-analytical study was conducted in Isfahan Alzahra hospital in 2013. Three hundred MS patients and 100 healthy individuals were determined. The distributed questionnaires related to MS patients and considering the descriptive statistics such as demographic variables. Data were analyzed by SPSS software (version 18) based on Chi-square test and independent T-test. RESULTS: Disease duration varied between 1 to 38 years: 30% (1-4 years), 38% (5-10 years), 20% (10-20 years), and 12% (more than 20 years). Significant relationship was observed between disease duration and tendency to type A (higher stress). This relation was positive and significant in Relapsing Remitting MS patients; but negative correlation was seen in Secondary Progressive MS patients. These patients tended to type B (lower stress) when disease duration increased. CONCLUSIONS: Individuals with disease duration of one year and less than one year tend to type A personality, while patients with increment of disease duration have tendency to type B.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1604
[Cu] Class update date: 160423
[Lr] Last revision date:160423
[Da] Date of entry for processing:160421
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.4103/2277-9175.178807

  8 / 197800 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text

[PMID]: 27099782
[Au] Autor:Baulina NM; Kulakova OG; Favorova OO
[Ad] Address:Pirogov Russian National Research Medical University, Ostrovityanova St., 1, Moscow, 117997, Russia ; Russian Cardiology Research and Production Complex, 3-rd Cherepkovskay St., 15a, Moscow, 121552 , Russia.
[Ti] Title:MicroRNAs: The Role in Autoimmune Inflammation.
[So] Source:Acta Naturae;8(1):21-33, 2016 Jan-Mar.
[Is] ISSN:2075-8251
[Cp] Country of publication:Russia (Federation)
[La] Language:eng
[Ab] Abstract:MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression at the post-transcriptional level through base-pairing predominantly with a 3'-untranslated region of target mRNA, followed by mRNA degradation or translational repression. Totally, miRNAs change, through a complex regulatory network, the expression of more than 60% of human genes. MiRNAs are key regulators of the immune response that affect maturation, proliferation, differentiation, and activation of immune cells, as well as antibody secretion and release of inflammatory mediators. Disruption of this regulation may lead to the development of various pathological conditions, including autoimmune inflammation. This review summarizes the data on biogenesis and the mechanisms of miRNA action. We discuss the role of miRNAs in the development and the action of the immune system, as well as in the development of an autoimmune inflammatory response. Special attention is given to the role of miRNAs in the autoimmune inflammation in multiple sclerosis, which is a serious socially significant disease of the central nervous system. Currently, a lot of research is focused on this problem.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1604
[Cu] Class update date: 160423
[Lr] Last revision date:160423
[Da] Date of entry for processing:160421
[St] Status:PubMed-not-MEDLINE

  9 / 197800 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26580489
[Au] Autor:Budde K; Zonnenberg BA; Frost M; Cheung W; Urva S; Brechenmacher T; Stein K; Chen D; Kingswood JC; Bissler JJ
[Ad] Address:Charité Universitätsmedizin, Berlin, Germany....
[Ti] Title:Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.
[So] Source:Br J Clin Pharmacol;81(5):958-70, 2016 May.
[Is] ISSN:1365-2125
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:AIMS: The purpose was to determine the exposure-response relationship of everolimus in patients with angiomyolipoma from the EXIST-2 trial and to analyze the correlation between exposure and plasma concentrations of angiogenic biomarkers in these patients. METHODS: One hundred and eighteen patients with angiomyolipoma associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM) were randomly assigned 2 : 1 to receive everolimus 10 mg (n = 79) or placebo (n = 39) once daily. Blood samples for determining everolimus concentration were collected at weeks 2, 4, 12, 24 and 48 during double-blind treatment. Plasma samples for biomarker analysis were collected at baseline and weeks 4, 12, 24, 36, 48 and at the end of treatment. Concentrations of eight angiogenic biomarkers associated with tumour growth were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: Peak and trough concentrations of everolimus in blood remained stable over time and similar to those reported in other indications. Substantial pharmacodynamic effects were observed in the everolimus, but not placebo, arm for three biomarkers: After 24 weeks of treatment, reduction of vascular endothelial growth factor D (VEGF-D) and collagen type IV (COL-IV) (mean fold-changes with 95% confidence intervals [CI] were 0.36 [0.33, 0.40], and 0.54 [0.51, 0.57], respectively, P < 0.001 for both), along with increased VEGF-A (mean fold-change of 1.59 [1.39, 1.80], P < 0.001), were seen. Furthermore, baseline VEGF-D and COL-IV levels were associated with angiomyolipoma size at baseline and with angiomyolipoma response to everolimus. CONCLUSIONS: These findings suggest that plasma angiogenic markers may provide an objective measure of patient response to everolimus.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1604
[Cu] Class update date: 160423
[Lr] Last revision date:160423
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1111/bcp.12834

  10 / 197800 MEDLINE  
              first record previous record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 27078146
[Au] Autor:Rosato R; Testa S; Bertolotto A; Confalonieri P; Patti F; Lugaresi A; Grasso MG; Toscano A; Giordano A; Solari A
[Ad] Address:Department of Psychology, University of Turin, Turin, Italy....
[Ti] Title:Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory.
[So] Source:PLoS One;11(4):e0153466, 2016.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: The Multiple Sclerosis Quality of Life-54 (MSQOL-54, 52 items grouped in 12 subscales plus two single items) is the most used MS specific health related quality of life inventory. OBJECTIVE: To develop a shortened version of the MSQOL-54. METHODS: MSQOL-54 dimensionality and metric properties were investigated by confirmatory factor analysis (CFA) and Rasch modelling (Partial Credit Model, PCM) on MSQOL-54s completed by 473 MS patients. Their mean age was 41 years, 65% were women, and median Expanded Disability Status Scale (EDSS) score was 2.0 (range 0-9.5). Differential item functioning (DIF) was evaluated for gender, age and EDSS. Dimensionality of the resulting short version was assessed by exploratory factor analysis (EFA) and CFA. Cognitive debriefing of the short instrument (vs. the original) was then performed on 12 MS patients. RESULTS: CFA of MSQOL-54 subscales showed that the data fitted the overall model well. Two subscales (Role Limitations-Physical, Role Limitations-Emotional) did not fit the PCM, and were removed; two other subscales (Health Perceptions, Social Function) did not fit the model, but were retained as single items. Sexual Satisfaction (single-item subscale) was also removed. The resulting MSQOL-29 consisted of 25 items grouped in 7 subscales, plus 4 single items. PCM fit statistics were within the acceptability range for all MSQOL-29 items except one which had significant DIF by age. EFA and CFA indicated adequate fit to the original two-factor (Physical and Mental Health Composites) hypothesis. Cognitive debriefing confirmed that MSQOL-29 was acceptable and had lost no key items. CONCLUSIONS: The proposed MSQOL-29 is 50% shorter than MSQOL-54, yet preserves key quality of life dimensions. Prospective validation on a large, independent MS patient sample is ongoing.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1604
[Cu] Class update date: 160423
[Lr] Last revision date:160423
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1371/journal.pone.0153466


page 1 of 19780 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information